Ontology highlight
ABSTRACT: Introduction
Understanding the impact of regulatory actions for medicines and enablers/barriers for positive health outcomes is fundamental to effective risk minimisation measures (RMM). Therefore, the Impact Strategy of the European Union (EU) Pharmacovigilance Risk Assessment Committee (PRAC) includes engagement with patient communities and healthcare professional (HCP) bodies regarding RMM. However, there is uncertainty on how best to obtain stakeholder input.Objectives
The objectives of this study were to (1) analyse stakeholder input at a public hearing and dedicated meeting for the 2017-18 EU procedure on valproate teratogenicity and (2) draw proposals for enhancing PRAC engagement.Methods
For the content analysis, the novel 'Analysing Stakeholder Safety Engag
SUBMITTER: Bahri P
PROVIDER: S-EPMC7847429 | biostudies-literature | 2021 Feb
REPOSITORIES: biostudies-literature